Specialty Pharmacy

A look at last week's top stories in the world of pharmacy.

The FDA did not identify any new or unexpected safety findings with pimavanserin (Nuplazid), nor findings that are inconsistent with the established safety profile currently described in the drug label.

Phase 3 trial results for dupilumab (Dupixent) demonstrate improvement in skin clearing, itch, and certain quality of life measurements for adolescents with atopic dermatitis.

The phase 3 PARADIGMS clinical trial is the first-ever study designed for children and adolescents aged 10 to 17 years old with relapsing forms of multiple sclerosis.

Top news of the day from across the health care landscape.

Patients with multiple sclerosis incur higher costs and experience lower health-related quality of life as their disability increases

Deaths due to poor-quality health care represent a substantial challenge for universal coverage in low- and middle-income countries.

Top news of the day from across the health care landscape

Sequential administration of HER2+ therapy and chemotherapy did not affect survival outcomes in patients with breast cancer.

The Patient Right to Know Drug Prices Act would prohibit insurers and prescription benefit managers from using gag clauses by health insurers and pharmacy benefit managers.

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines for kidney cancer to include new recommendations for cabozantinib tablets.

Tildrakizumab (Ilumetri) received approval by the European Commission for the treatment of moderate-to-severe chronic plaque psoriasis.

Top news of the day from across the health care landscape.

When used in combination with an anti-PD-L1 therapy, a novel vaccine plus Diprovocim increased survival in mice with melanoma.

Study shows that it’s cost-effective to use the livers of HCV-positive patients even with the cost of direct-acting antiviral drugs to cure the virus.

Study identifies receptor as potential target for reversing liver damage and preventing progression to cancer.

Top news of the day from across the health care landscape.

Officials with the FDA have approved fremanezumab-vfrm (Ajovy, Teva) for the preventive treatment of migraine in adults.

Growth in midlife mortality includes conditions such as heart disease, liver cancer, pulmonary disease, obesity, and neurologic disorders.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, talks about why pharmacists should pursue continuing education to benefit their patients.

A second unexpected impurity was shown in 3 lots of Torrent Pharmaceuticals’ recalled drug products during an ongoing FDA investigation.

Pamrevlumab is advancing towards phase 3 clinical development for idiopathic pulmonary fibrosis early next year.

Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with hairy cell leukemia.

The FDA has accepted for review Regeneron Pharmaceuticals’ supplemental Biologics License Application (sBLA) of aflibercept (EYLEA Injection) to treat diabetic retinopathy.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Tocilizumab’s newest formulation offers an additional administration option for children diagnosed systemic juvenile idiopathic arthritis, a rare and debilitating disease.